Treatment of endocrinologic male sexual dysfunction.
Erectile dysfunction affects 20 million to 30 million men in the United States, and it has been reported that a significant number of impotent men (2.1% to 23%) have subnormal serum testosterone levels. A decline in serum levels of testosterone accompanies normal aging in men; however, the pathophysiological and clinical consequences of this decline are unknown. Appropriate hormonal therapy for men with hypogonadism requires an understanding of the normal physiologic regulation of the testes and the pathophysiology of underlying testicular dysfunction. This article reviews those mechanisms.
Nehra
A
A
Department of Urology, Mayo Clinic Rochester, Minn., USA.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000375:Aging / Q000187:drug effects* / Q000502:physiology*; D000465:Algorithms; D003663:Decision Trees; D016903:Drug Monitoring / Q000379:methods; D007172:Erectile Dysfunction / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008403:Mass Screening / Q000379:methods; D012307:Risk Factors; D013739:Testosterone / Q000172:deficiency* / Q000502:physiology / Q000627:therapeutic use*; D014481:United States
D013739:Testosterone